<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04304768</url>
  </required_header>
  <id_info>
    <org_study_id>20200178</org_study_id>
    <nct_id>NCT04304768</nct_id>
  </id_info>
  <brief_title>Opioid, HIV and Immune System</brief_title>
  <official_title>Immune Dysfunction in HIV+ Opioid Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to evaluate blood samples from HIV infected and non-HIV&#xD;
      infected people opioid and non opioid users to understand how opioid affect the immune&#xD;
      responses (body defenses against infection) to the flu vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the antibody response</measure>
    <time_frame>Baseline, 4 weeks, 6 months</time_frame>
    <description>Antibody response as measured by the serum vaccine antigen specific hemagglutination inhibition antibody levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune activation levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Activation of T and B cells from peripheral blood mononuclear cells assessed via flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation biomarker levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Plasma levels of Interleukin (IL)-6, IL-8, IL-12, IL-17, IL-22, Tumor necrosis factor (TNF) and monocyte activation markers soluble CD14 and soluble CD163 will be assessed via Magpix. All the biomarkers will be measured in nanograms/milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating T follicular helper cell function</measure>
    <time_frame>Week 4</time_frame>
    <description>T follicular helper cell function measured from peripheral blood mononuclear cells via flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating T follicular helper cell frequency</measure>
    <time_frame>Week 4</time_frame>
    <description>T follicular helper cell frequency measured from peripheral blood mononuclear cells via flow cytometry.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Immune Defect</condition>
  <arm_group>
    <arm_group_label>HIV positive opioid users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will continue their standard of care antiretroviral therapy (ART) and receive flu vaccination as part of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV positive non-opioid users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will continue their standard of care antiretroviral therapy (ART) and receive flu vaccination as part of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV negative opioid users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive flu vaccination as part of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV negative non-opioid users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive flu vaccination as part of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone Quadrivalent</intervention_name>
    <description>0.5 ml prefilled syringe administrated intramuscularly</description>
    <arm_group_label>HIV negative non-opioid users</arm_group_label>
    <arm_group_label>HIV negative opioid users</arm_group_label>
    <arm_group_label>HIV positive non-opioid users</arm_group_label>
    <arm_group_label>HIV positive opioid users</arm_group_label>
    <other_name>Influenza vaccination</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For Opioid (OP) users/non-users:&#xD;
&#xD;
          1. OP users - prescribed opioids for at least the past 90 days; or injecting opioids for&#xD;
             at least 90 days&#xD;
&#xD;
          2. Opioid never-users in the past year&#xD;
&#xD;
        Additional criteria for OP users:&#xD;
&#xD;
          1. OP use for 90 days pre-flu vaccination&#xD;
&#xD;
          2. Continued OP use for 4 weeks post flu vaccination&#xD;
&#xD;
        For HIV positive participants:&#xD;
&#xD;
        1) HIV infection, as documented by any licensed ELISA kit and confirmed by Western blot at&#xD;
        any time prior to study entry. Participants on ART as a result of prior HIV documented&#xD;
        infection will not be required to provide proof of diagnosis of HIV infection.&#xD;
&#xD;
        Additional criteria for HIV positive participants:&#xD;
&#xD;
          1. On ART for at least 1 year with plasma pending viral load (VL) &lt;200 copies/mL.&#xD;
             Occasional viral blips up to 1000 copies/ml also acceptable provided the patients are&#xD;
             on continuing treatment&#xD;
&#xD;
          2. CD4 count available in the prior 6 months and &gt;200/mm3&#xD;
&#xD;
          3. Undetectable viral load (&lt; 200 copies/mL)&#xD;
&#xD;
        For HIV negative participants:&#xD;
&#xD;
        1) Documented negative HIV test, either by any licensed ELISA or rapid tests within the&#xD;
        past 6 months.&#xD;
&#xD;
        For all participants:&#xD;
&#xD;
          1. Individuals age 18-60 yrs .&#xD;
&#xD;
          2. No history of other immunodeficiency disorders&#xD;
&#xD;
          3. Not on steroid or other immunosuppressive/immunomodulators medications.&#xD;
&#xD;
          4. No active malignancies.&#xD;
&#xD;
          5. No contraindication to receive influenza vaccination (allergy to chicken eggs or to&#xD;
             any other substance of the vaccine).&#xD;
&#xD;
          6. Agreeable to receive the influenza vaccination.&#xD;
&#xD;
          7. Agreeable to participate in study for a complete course of study full visits.&#xD;
&#xD;
          8. Able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to receive influenza vaccination (allergy to chicken eggs or to any&#xD;
             other substance of the vaccine).&#xD;
&#xD;
          2. Non-adherence to ART for HIV+&#xD;
&#xD;
          3. Unable to provide informed consent.&#xD;
&#xD;
          4. Other comorbid conditions such as diabetes mellitus type 2 (DMT2)&#xD;
&#xD;
          5. Influenza vaccination already given during the current vaccination season.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Savita Pahwa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Savita Pahwa, MD</last_name>
    <phone>3052437732</phone>
    <email>spahwa@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suresh Pallikkuth, PhD</last_name>
    <phone>3052435315</phone>
    <email>SPallikkuth@med.miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suresh Pallikkuth, PhD</last_name>
      <phone>786-201-9897</phone>
      <email>SPallikkuth@med.miami.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Savita Pahwa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Flu vaccine response and HIV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

